Ragweed Allergy pipeline therapeutics constitutes close to 5 molecules. which approximately 5 molecules are developed by Companies. Our latest report Ragweed Allergy - Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Ragweed Allergy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
Ragweed Allergy Ragweed allergy occurs when ragweed pollen in the air enters the nose and throat of people who are allergic to that pollen, it can cause allergy and asthma symptoms. Symptoms include sneezing, runny or stuffy nose, itchy throat or inside of ears, hives, and swollen eyelids and itchy eyes. Treatment includes decongestant, antihistamine and nasal corticosteroid. The molecules developed by Companies in Phase II, Preclinical and Unknown stages are 1, 3 and 1 respectively.
Furthermore, this report also reviews of key players involved in therapeutic development for Ragweed Allergy and features dormant and discontinued projects.
Key Topics Covered:
- Ragweed Allergy Overview
- Therapeutics Development
- Pipeline Products for Ragweed Allergy - Overview
- Pipeline Products for Ragweed Allergy - Comparative Analysis
- Ragweed Allergy - Therapeutics under Development by Companies
- Ragweed Allergy - Therapeutics under Investigation by Universities/Institutes
- Ragweed Allergy Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Ragweed Allergy - Products under Development by Companies
- Ragweed Allergy - Products under Investigation by Universities/Institutes
- Ragweed Allergy - Companies Involved in Therapeutics Development
- Anergis SA
- Biomay AG
- Circassia Pharmaceuticals Plc
- Immunomic Therapeutics, Inc.
For more information about this report visit http://www.researchandmarkets.com/research/jvk8mn/ragweed_allergy